Protocol Ledger

NCT04620187 · Phase II · RECRUITING

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Interventional Phase II clinical trial protocol NCT04620187 sponsored by Dana-Farber Cancer Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-24 Enrollment: 37 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04620187
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)37 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04620187
Protocol FieldVerified Registry Value
NCT IdentifierNCT04620187
Consolidated Lead SponsorDana-Farber Cancer Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment37 participants (ESTIMATED)
Registered Start Date2020-12-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI